A5089022163- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- vaccines and immunoinformatics approaches
- Cervical Cancer and HPV Research
- Virus-based gene therapy research
- Immune Cell Function and Interaction
- Pharmacogenetics and Drug Metabolism
- Viral Infections and Outbreaks Research
- Hepatitis B Virus Studies
- Statistical Methods and Inference
- Immune cells in cancer
- Animal Virus Infections Studies
- Data Management and Algorithms
- RNA Interference and Gene Delivery
- Lung Cancer Treatments and Mutations
- Gene expression and cancer classification
- Glycosylation and Glycoproteins Research
- Data Mining Algorithms and Applications
- Advanced Clustering Algorithms Research
- Cancer, Lipids, and Metabolism
- Ovarian cancer diagnosis and treatment
- Tannin, Tannase and Anticancer Activities
- Bioinformatics and Genomic Networks
- PARP inhibition in cancer therapy
Transgene (France)
2014-2024
Zimmer Biomet (France)
2023
Helsinki University Hospital
2019
Antwerp University Hospital
2019
Montefiore Medical Center
2019
Albert Einstein College of Medicine
2019
University of Arizona
2019
University of Alabama at Birmingham
2019
University of Virginia Health System
2019
Roche (Switzerland)
2019
Treatment of chronic hepatitis B (CHB) typically requires life-long administration drugs. Cohort and pre-clinical studies have established the link between a functional T-cell-mounted immunity resolution infection. TG1050 is an adenovirus 5-based vaccine that expresses HBV polymerase domains core surface antigen has shown immunogenicity antiviral effects in mice. We performed phase 1 clinical trial to assess safety explore early efficacy CHB patients. This randomized, double blind,...
BackgroundWhile prophylactic human papillomavirus (HPV) vaccination exists, women are still developing cervical intraepithelial neoplasia (CIN) grade 2 or 3 for which an immunotherapeutic, non-surgical, approach may be effective. The primary aim was to assess the efficacy of tipapkinogen sovacivec (TS) vaccine in achieving histologic resolution CIN2/3 associated with high risk (HR) HPV types.MethodsWomen 18 years and older who had confirmed were enrolled a randomized, double blind,...
<h3>Background</h3> Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard chemotherapy, displayed longer overall survival comparison that of treated with chemotherapy alone. Our study intended establish the association between vaccine-induced T responses against tumor associated antigens (TAA) targeted by vaccine. <h3>Method</h3> The TIME trial was placebo-controlled, randomized phase II...
The putative contribution of natural killer (NK) cells to immunosurveillance in non-small cell lung cancer (NSCLC) has been an ongoing conundrum. Here, we used a readily standardizable quantitative real time polymerase chain reaction (qRT-PCR) measure the expression NK receptors total peripheral blood mononuclear (PBMC) from healthy volunteers (HV), patients with gastrointestinal stromal tumors (GIST), neuroblastoma (NB), melanoma or NSCLC. We quantified NCR1 (which codes for NKp46) and NCR3...
Background This study describes the effect of TG4010 vaccine on Health related Quality Life (HRQOL) in patients with stage IIIb and IV non–small-cell lung cancer (NSCLC). Methods 148 advanced NSCLC expressing MUC1 were randomly assigned to receive plus chemotherapy or alone. HRQOL was assessed Functional Assessment Cancer Therapy-Lung (FACT-L) at baseline every 6 weeks until disease progression. Time definitive deterioration (TUDD) four well-being dimensions FACT-L physical (PWB), functional...
6082 Background: Despite adjuvant therapy, over 50% of surgically treated head and neck squamous cell carcinoma (HNSCC) patients (pts) experience a recurrence disease. Systemic stimulation cellular immunity against tumor mutations using viral vaccine may be an ideal modality to clear residual cancer cells. For this purpose, we developed pipeline for the design TG4050, personalized (PCV) Modified Vaccinia Ankara (MVA) vector. We report here preliminary safety immunogenicity data from phase I...
3027 Background: TG4010 is a targeted immunotherapy product. It was tested in combination with first-line chemotherapy randomized, controlled, multicenter phase II study patients advanced non small cell lung cancer (NSCLC) (ASCO 2008- Abstract No 8023) Methods: In addition to clinical endpoints, immune parameters were tested. Blood samples drawn prior therapy (day1) as well at day 43 (after 6 injections of TG4010). Lymphocyte populations assessed by 5-color flow cytometry. Plasma for...
3034 Background: TG4010 is an immunotherapy using attenuated and modified poxvirus (MVA) coding for MUC1 interleukin-2. A previous study showed that the baseline level of Triple Positive Activated Lymphocytes (TrPAL, CD16+CD56+CD69+) might be a predictive biomarker efficacy in NSCLC. Methods: TIME double blind, placebo-controlled phase IIb/III study. The IIb part compared first line chemotherapy combined with or placebo further assessed value TrPAL. Eligibility criteria included stage IV...
Following acute stress such as trauma or sepsis, most of critically ill elderly patients become immunosuppressed and susceptible to secondary infections enhanced mortality. We have developed a virus-based immunotherapy encoding human interleukin-7 (hIL-7) aiming at restoring both innate an adaptative immune homeostasis in these patients. assessed the impact this encoded hIL-7 on ex vivo functions T cells from PBMC immunosenescent with without hip fracture. T-cell phenotyping was...
Abstract Persistence of an immunosuppressive state plays a role in septic patient morbidity and late mortality. Both innate adaptive pathways are impaired, pointing toward the need for immune interventions targeting both arms system. We developed virotherapy using nonpropagative modified vaccinia virus Ankara (MVA), which harbors intrinsic capacity to stimulate immunity, deliver IL-7, potent activator immunity. The rMVA–human IL-7 (hIL-7)–Fc encoding hIL-7 fused human IgG2-Fc was engineered...
TPS7610 Background: TG4010 is an immunotherapy product based on a poxvirus (MVA) coding for the MUC1 tumor-associated antigen and interleukin-2. A previous study, TG4010.09, which evaluated combination of first-line chemotherapy with without in advanced NSCLC, achieved its primary endpoint 6-month progression-free survival (PFS) showed that pre-treatment level activated Natural Killer (aNK) cells may be potential predictive biomarker efficacy (E. Quoix et al., Lancet Oncol. 2011;12:1125-33)....
<h3>Background</h3> T cells targeting tumor specific mutations drive anti-tumor immune responses. TG4050 is a novel viral-based personalized cancer vaccine, encoding up to 30 patient- and tumor-specific sequences bearing in-silico predicted class I II epitopes. may prime an adaptive response against antigens prevent relapse in patients with locally advanced resected HNSCC. (NCT04183166) <h3>Methods</h3> Eligible stage III or IV HPV-negative HNSCC were randomized after completion of standard...
We propose a new methodology for selecting and ranking covariates associated with variable of interest in context high-dimensional data under dependence but few observations. The successively intertwines the clustering covariates, decorrelation using Factor Latent Analysis, selection aggregation adapted methods finally ranking. A simulation study shows inside different clusters covariates. first apply our method to transcriptomic 37 patients advanced non-small-cell lung cancer who have...
Article Meeting Report: From human genetic variations to prediction of risks and responses drugs the environment was published on March 1, 2007 in journal Clinical Chemistry Laboratory Medicine (CCLM) (volume 45, issue 3).